携带共突变的非小细胞肺癌患者可能从程序性死亡受体1配体（PD-L1）抑制剂中获益。
Non-small-cell lung cancer patients harboring co-mutation could benefit from a PD-L1 inhibitor.
作者信息
Zhang Chenyue, Wang Kai, Lin Jiamao, Wang Haiyong
机构信息
Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Key Laboratory of Epigenetics & Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, China.
出版信息
Future Oncol. 2022 Sep;18(27):3031-3041. doi: 10.2217/fon-2022-0295. Epub 2022 Sep 6.
To explore the association between mutation and atezolizumab in non-small-cell lung cancer (NSCLC) patients. Patients with NSCLC from the POPLAR and OAK studies were included. Kaplan-Meier analysis was performed to detect progression-free survival (PFS) and overall survival (OS). PFS and OS were compared using multivariate Cox regression analysis. OS was significantly longer with atezolizumab compared with docetaxel among co-mutant NSCLC patients (hazard ratio [HR]: 0.014; 95% CI: 0.000-0.721). There is no significant OS difference between atezolizumab versus docetaxel for -mutant NSCLC patients (HR: 0.831; 95% CI: 0.473-1.458). There is no significant OS difference between atezolizumab versus docetaxel for -mutant NSCLC patients (HR: 1.354; 95% CI: 0.528-3.472). PD-L1 inhibitors may bring OS benefits for patients with NSCLC harbored co-mutation.
探讨非小细胞肺癌（NSCLC）患者中突变与阿特珠单抗之间的关联。纳入了来自POPLAR和OAK研究的NSCLC患者。进行Kaplan-Meier分析以检测无进展生存期（PFS）和总生存期（OS）。使用多变量Cox回归分析比较PFS和OS。在共突变NSCLC患者中，与多西他赛相比，阿特珠单抗治疗的OS显著更长（风险比[HR]：0.014；95%置信区间：0.000-0.721）。对于-突变NSCLC患者，阿特珠单抗与多西他赛之间的OS无显著差异（HR：0.831；95%置信区间：0.473-1.458）。对于-突变NSCLC患者，阿特珠单抗与多西他赛之间的OS无显著差异（HR：1.354；95%置信区间：0.528-3.472）。PD-L1抑制剂可能会给携带共突变的NSCLC患者带来OS益处。
Zotero 插件